NeoGenomics, Inc.
NASDAQ:NEOMedical - Diagnostics & Research
+$0.63 today
- Market cap
- $1.99B
- Beta
- 1.81
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.84
Volume 1.09M
Average 1.94M
NEO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
NeoGenomics, Inc.NASDAQ: NEO
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin dips below year-ago levels
Q2 FY2026 selling, general & admin of $90.89M fell 5.1% year over year, behind the +0.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 1.5% from the prior quarter. Over 3 fiscal years it compounded at +9.5% a year.
Context
- Selling, general & admin amounted to 50.2% of revenue in FY2025, up 3.2 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 8 analysts of $416.54M (+14.0%) for the fiscal year ending Dec 2026, a slowdown from the +17.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $90.89M+1.5% QoQ
- Last fiscal yearDec 2025
- $365.34M+17.7% YoY
- LTMJun 2026
- $359.09M+0.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 365.34M USD
- Year-over-year change
- +17.7%
- 4-year CAGR
- +6.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 365.34M | +17.7% |
| FY2024 | 2024-12-31 | 310.49M | +10.9% |
| FY2023 | 2023-12-31 | 279.96M | +0.7% |
| FY2022 | 2022-12-31 | 277.91M | -2.1% |
| FY2021 | 2021-12-31 | 283.94M | — |
Selling, General & Admin vs competitors
How NEO compares with its peers on the latest reported figures
- NEO's LTM Jun 2026 selling, general & admin of $359.09M is the 3rd highest of the 10 companies compared; the peer median is $235.6M.
- Its year-over-year change of +0.6% is the 7th highest of 10, against a peer median of +12.9%.
- Selling, general & admin amounts to 46.9% of revenue for NEO, versus a peer median of 69.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $951.07M | +44.5% | +15.0% | 74.4% | |
| LTM Mar 2026 | $537.7M | -3.2% | +1.5% | 64.9% | |
| LTM Jun 2026 | $359.09M | +0.6% | +9.5% | 46.9% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $292.26M | +58.0% | -10.9% | 64.3% |
| LTM Jun 2026 | $291.09M | -3.7% | -2.4% | 176.1% | |
| LTM Mar 2026 | $235.6M | +12.1% | +17.0% | 69.3% | |
| LTM Jun 2026 | $201.58M | -7.5% | +6.6% | 35.9% | |
| LTM Mar 2026 | $91.36M | +13.7% | +12.5% | 95.1% | |
| LTM Mar 2026 | $59.21M | +26.4% | -5.7% | 91.8% | |
| LTM Mar 2026 | $47.48M | +12.9% | -3.6% | 69.4% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding NEO) | $235.6M | +12.9% | +1.5% | 69.4% | |
Competitors are the stored peer set for NEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 484.33M | 509.73M | 591.64M | 660.57M | 727.33M |
| Cost of Revenue | 297.27M | 321.83M | 347.04M | 370.47M | 444.79M |
| Gross Profit | 187.06M | 187.9M | 244.6M | 290.1M | 282.54M |
| Gross Margin | 38.6% | 36.9% | 41.3% | 43.9% | 38.8% |
| Research & Development | 21.87M | 30.33M | 27.31M | 31.16M | 37.08M |
| Selling, General & Admin | 283.94M | 277.91M | 279.96M | 310.49M | 365.34M |
| Operating Expenses | 305.81M | 345.52M | 352.34M | 382.21M | 348.62M |
| Depreciation & Amortization | 53.35M | 69.43M | 72.58M | 72.55M | 67.82M |
| EBITDA | 46.5M | (82.33M) | (17.61M) | (1.51M) | (38.69M) |
| EBITDA Margin | 9.6% | -16.2% | -3.0% | -0.2% | -5.3% |
| Operating Income | (118.75M) | (157.62M) | (107.74M) | (92.11M) | (66.08M) |
| Operating Margin | -24.5% | -30.9% | -18.2% | -13.9% | -9.1% |
| Interest Income | 3.14M | 6.08M | 16.9M | 18.43M | 9.07M |
| Interest Expense | 8.22M | 7.58M | 6.91M | 6.62M | 3.75M |
| Other Income / Expenses | 103.68M | (1.72M) | 10.64M | 11.43M | (44.19M) |
| Income Before Tax | (15.08M) | (159.34M) | (97.1M) | (80.68M) | (110.27M) |
| Pre-Tax Margin | -3.1% | -31.3% | -16.4% | -12.2% | -15.2% |
| Income Tax Expense | (6.73M) | (15.09M) | (9.13M) | (1.95M) | (2.24M) |
| Net Income | (8.35M) | (144.25M) | (87.97M) | (78.73M) | (108.03M) |
| Net Margin | -1.7% | -28.3% | -14.9% | -11.9% | -14.9% |
| EPS (Basic) | (0.07) | (1.16) | (0.70) | (0.62) | (0.84) |
| EPS (Diluted) | (0.07) | (1.16) | (0.70) | (0.62) | (0.84) |
| Weighted Avg Shares | 119.96M | 124.22M | 125.5M | 126.66M | 128.1M |
| Weighted Avg Shares (Diluted) | 119.96M | 124.22M | 125.5M | 126.66M | 128.1M |
NeoGenomics, Inc.
NASDAQ:NEO
Intrinsic Alpha fair value
Locked
Current Price
$15.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.